Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is seeking participants who: * Are 12 years of age or older * Have a diagnosis of alopecia areata * Have lost 50% or more of the hair on their scalp * Do not have any other conditions that causes hair loss * Are willing to stop all other treatments that they may be taking for alopecia areata About 550 participants will take part in in this study. Participants will be chosen by chance, like drawing names out of a hat, to receive 1 of 2 different amounts of ritlecitinib (50 mg and 100 mg) taken by mouth once daily. The 2 doses of ritlecitinib in this study will be compared to each other and also to data from previous studies. This will help to see if the 100 mg dose of ritlecitinib is safe and effective. People will be in this study for about 13 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as: * alopecia areata assessment, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG (electrocardiogram), * photographs of the scalp and eyes. Participants will also be asked to complete questionnaires about their alopecia areata.
Conditions Studied
Interventions
- DRUG Ritlecitinib 50 mg
- DRUG Ritlecitinib 100 mg
- DRUG Placebo - 50 mg
- DRUG Placebo - 100 mg
Study Locations (20)
Florida
- Alliance for Multispecialty Research, LLC — Fort Myers
- Robert B. Pritt, DO, PA — Fort Myers
- Solutions Through Advanced Research — Jacksonville
- Pediatric Skin Research — Miami
- Skin Research of South Florida — Miami
- ForCare Clinical Research — Tampa
- Olympian Clinical Research - Tampa - Memorial Highway — Tampa
California
- Doc1 Healthcare Systems — Brea
- California Dermatology & Clinical Research Institute — Encinitas
- Marvel Clinical Research — Huntington Beach
- Southern California Clinical Research — Santa Ana
Indiana
- Indiana University Health University Hospital Adult Outpatient Center — Indianapolis
- Indiana University School of Medicine - Indiana CTSI Clinical Research Center — Indianapolis
- Sidney & Lois Eskenazi Health Center — Indianapolis
- Dawes Fretzin Clinical Research Group, LLC — Indianapolis
Arkansas
- Burke Pharmaceutical Research — Hot Springs
Connecticut
- Brett King MD, LLC — Fairfield
Illinois
- Endeavor Health — Skokie
Iowa
- University of Iowa — Iowa City
Maryland
- Callender Center for Clinical Research — Glenn Dale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2027-03-09 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06873945
The ClinicalTrials.gov registry entry for NCT06873945 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 4 interventions — of which Ritlecitinib 50 mg is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06873945 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Florida, California, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06873945 about?
NCT06873945 is a clinical study titled "A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata". The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 5...
What is the current status of trial NCT06873945?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2025-04-01. Estimated completion is 2027-03-09.
What conditions does trial NCT06873945 study?
This clinical trial studies the following conditions: Alopecia Areata. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06873945?
The interventions under investigation include: Ritlecitinib 50 mg (DRUG), Ritlecitinib 100 mg (DRUG), Placebo - 50 mg (DRUG), Placebo - 100 mg (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06873945?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06873945 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.